FDA document reveals 86% of children suffered adverse reactions to Pfizer vaccine!
WASHINGTON (PNN) - May 29, 2021 - An Amerikan Gestapo Food and Drug Administration division (FDA) document reveals that 86% of children between the ages of 12 and 15 who participated in Pfizer vaccine trials experienced adverse effects.
This troubling report, numbered 144413, only calls into question the use of the vaccine in children in that age range, approved on May 10 by the FDA.
There is a difference between the 1127 children who received the first dose of the mRna injection and 1097 who received the second dose, calling into question what happened to these 30 children who did not show up for the second dose; whether they withdrew from the trials or met an even worse fate.
The numbers shown by the trial were more than alarming. Even though 86% of the children suffered side effects after the first dose, researchers continued experimenting and injected them with a second mRna shot.
Other data to note:
- 65% of the children suffered headaches.
- 66% of the children had a fever
- About 44% of the children suffered “moderate” side effects, which they defined as “interfering with activity.”
They also suffered other side effects such as diarrhea, chills, joint pain, vomiting, and muscle pain.
Despite all these conclusive data, the FDA deemed that the vaccine does not pose a danger to children and approved its emergency use.
FDA Acting Commissioner Janet Woodcock said, “Parents and guardians can rest assured that the agency undertook a rigorous and thorough review of all available data, as we have with all of our COVID-19 vaccine emergency use authorizations.”
This last statement does not seem to be in line with the reality of the results of the trials conducted, unless the FDA really thinks that 86% side effects are normal and it does not care about putting the lives of young people at risk, not to mention that there are also possible medium and long-term adverse effects that could be generated in those who receive this experimental mRna injection.